Device industry representatives pressed CDRH during a June 5 meeting to better manage draft guidance documents to ensure they don’t remain in that unresolved phase for too long and that FDA staffers do not rely on a draft guidance as if it is established policy.
“Draft guidances should be finalized in reasonable timeframes,” Janet Trunzo, AdvaMed’s senior executive VP of technology and regulatory affairs, insisted...